Quick Answer
Gain Therapeutics, Inc. reported Stockholders Equity of $18.56 million for the year ending 2025.
- Gain Therapeutics, Inc. showed an increase of +152.9% in Stockholders Equity from 2024 to 2025.
- This data is from Gain Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $70.4 thousand | Q2 2020: -$476.6 thousand | Q3 2020: $7.83 million | Q1 2021: $44.46 million | Q2 2021: $41.39 million | Q3 2021: $37.55 million | Q1 2022: $31.83 million | Q2 2022: $27.02 million | Q3 2022: $22.66 million | Q1 2023: $15.14 million | Q2 2023: $11.09 million | Q3 2023: $7.33 million | Q1 2024: $8.64 million | Q2 2024: $11.78 million | Q3 2024: $8.91 million | Q1 2025: $5.78 million | Q2 2025: $3.70 million | Q3 2025: $5.91 million.
- Over the full 7 years of available data (2019 to 2025), Gain Therapeutics, Inc.'s Stockholders Equity has grown by 4,226.8%.
- Historical annual values: Fiscal year 2025: $18.56 million | Fiscal year 2024: $7.34 million | Fiscal year 2023: $12.58 million | Fiscal year 2022: $18.88 million | Fiscal year 2021: $34.82 million | Fiscal year 2020: $6.20 million | Fiscal year 2019: -$449.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: